var data={"title":"Ticlopidine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ticlopidine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7054?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ticlopidine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ticlopidine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709984\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Ticlopidine HCl can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis and thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neutropenia/agranulocytosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Among 2048 patients in clinical trials, there were 50 cases (2.4%) of neutropenia (less than 1200 neutrophils/mm<sup>3</sup>), and the neutrophil count was below 450/mm<sup>3</sup> in 17 of these patients (0.8% of the total population).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">TTP:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">One case of TTP was reported during clinical trials. Based on postmarketing data, US physicians reported about 100 cases between 1992 and 1997. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated TTP may be as high as 1 case in every 2000 to 4000 patients exposed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Aplastic anemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aplastic anemia was not seen during clinical trials in stroke patients, but US physicians reported about 50 cases between 1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated aplastic anemia may be as high as 1 case in every 4000 to 8000 patients exposed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring of clinical and hematologic status:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe hematologic adverse reactions may occur within a few days of the start of therapy. The incidence of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately 4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks of therapy. The incidence of the hematologic adverse reactions declines thereafter. Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more than 3 months of treatment.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hematological adverse reactions cannot be reliably predicted by any identified demographic or clinical characteristics. During the first 3 months of treatment, patients receiving ticlopidine HCl must, therefore, be hematologically and clinically monitored for evidence of neutropenia or TTP. If any such evidence is seen, ticlopidine HCl should be immediately discontinued.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227763\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Ticlopidine;</li>\n      <li>Teva-Ticlopidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227804\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Antiplatelet Agent, Thienopyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227767\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Ticlopidine is no longer available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stroke prevention:</b> Oral: 250 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Overall, the use of ticlopidine is no longer recommended for this indication and has largely been replaced by clopidogrel (Lindsay 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227768\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: 250 mg twice daily with food; dosage in older patients has not been determined; however, in two large clinical trials, the average age of subjects was 63 and 66 years. A dosage decrease may be necessary if bleeding occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6759555\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustment provided in the manufacturer's labeling. While there were no statistically significant differences in ADP-induced platelet aggregation, AUC increases and clearance decreases were seen in patients with mild to moderate renal impairment. However, bleeding time may be prolonged in patients with moderate renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6759556\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling. Use with caution. Use is contraindicated in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227744\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27727039\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Ticlopidine is no longer available in the US.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227747\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227746\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Platelet aggregation inhibitor that reduces the risk of thrombotic stroke in patients who have had a stroke or stroke precursors (<b>Note:</b> Due to its association with life-threatening hematologic disorders, ticlopidine should be reserved for patients who are intolerant to aspirin, who have failed aspirin therapy, or who are not eligible to receive other antiplatelet therapy.)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9961827\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Ticlopidine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to availability of safer, effective alternatives (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Ticlopidine is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227736\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs which may affect hemostasis, bleeding is associated with ticlopidine. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the use of multiple agents which alter hemostasis and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperlipidemia (8% to 10%; within 1 month of therapy), increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (13%; may be chronic)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5%), pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (7%), nausea (7%), gastrointestinal pain (4%), flatulence (2%), vomiting (2%), anorexia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (2%), purpura (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&gt;2 x upper limit of normal: 8%), abnormal hepatic function tests (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylaxis, angioedema, aplastic anemia, arthropathy, bone marrow depression, bronchiolitis obliterans organizing pneumonia,  conjunctival hemorrhage, ecchymosis, eosinophilia, epistaxis, erythema multiforme, erythema nodosum, exfoliative dermatitis, gastrointestinal hemorrhage, headache, hematuria, hemolytic anemia, hepatic necrosis, hepatitis, hypermenorrhea, hypersensitivity pneumonitis, hyponatremia, increased serum bilirubin, intracranial hemorrhage, immune thrombocytopenia, increased serum creatinine, jaundice, maculopapular rash, myositis, nephrotic syndrome, pain, pancytopenia, peptic ulcer, peripheral neuropathy, positive ANA titer, renal failure, sepsis, serum sickness, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocythemia, thrombotic thrombocytopenic purpura (TTP), tinnitus, urticaria, vasculitis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227750\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ticlopidine or any component of the formulation; active pathological bleeding such as peptic ulcer bleeding or intracranial hemorrhage; severe liver impairment; hematopoietic disorders (neutropenia, thrombocytopenia, or a past history of TTP or aplastic anemia); hemostatic disorders</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227733\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: <b> [US Boxed Warning]: May cause life-threatening hematologic reactions, including neutropenia, agranulocytosis, thrombotic thrombocytopenia purpura (TTP), and aplastic anemia.</b> Routine monitoring is required (see Monitoring Parameters). Monitor for signs and symptoms of neutropenia including WBC count. Discontinue if the absolute neutrophil count falls to &lt;1,200/mm<sup>3</sup> or if laboratory signs of TTP or aplastic anemia occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous thienopyridine hypersensitivity. Use of ticlopidine is contraindicated in patients with hypersensitivity to ticlopidine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with platelet disorders, bleeding disorders and/or at increased risk for bleeding (eg, PUD, trauma, or surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment. Use is contraindicated with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment (experience is limited); bleeding times may be significantly prolonged and the risk of hematologic adverse events (eg, neutropenia) may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulants and platelet aggregation inhibitors: Use with caution in patients receiving either anticoagulants (eg, heparin, warfarin) or other platelet aggregation inhibitors; bleeding risk is increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12 </sub>receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should <i>not</i> be discontinued); however, dual antiplatelet therapy should <i>not </i>be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery stents: In patients who have received bare-metal or drug-eluting stents (sirolimus or paclitaxel), premature interruption of antiplatelet therapy may result in stent thrombosis with subsequent fatal and nonfatal myocardial infarction. If ticlopidine is used, duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement (Levine, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elective surgery: Consider discontinuing 10 to 14 days before elective surgery (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227797\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227738\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9996&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: CYP2B6 Inhibitors (Weak) may increase the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Ticlopidine may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Liposomal): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Liposomal) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Ticlopidine may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Ticlopidine may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227759\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Ticlopidine bioavailability may be increased (20%) if taken with food. High-fat meals increase absorption, antacids decrease absorption. May cause upset stomach. Management: Take with food to reduce stomach upset.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227740\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13459612\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have not been observed in animal reproduction studies; a case report has demonstrated the safe use of ticlopidine in pregnant women (Ueno 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917341\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ticlopidine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227742\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of bleeding; CBC with differential at baseline prior to treatment initiation and then weekly for the first 3 months of therapy; more frequent monitoring is recommended for patients whose absolute neutrophil counts have been consistently declining or are 30% less than baseline values. The peak incidence of TTP occurs between 3-4 weeks, the peak incidence of neutropenia occurs at approximately 4-6 weeks, and the incidence of aplastic anemia peaks after 4-8 weeks of therapy. Few cases have been reported after 3 months of treatment. Liver function tests (alkaline phosphatase and transaminases) should be performed in the first 4 months of therapy if liver dysfunction is suspected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227732\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ticlopidine requires <i>in vivo</i> biotransformation to an unidentified active metabolite. This active metabolite irreversibly blocks the P2Y12 component of ADP receptors, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by ticlopidine are affected for the remainder of their lifespan. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227749\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 3-5 days; serum levels do not correlate with clinical antiplatelet activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Parent drug: 98%; &lt;15% bound to alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic; has at least 1 active metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60%); feces (23%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227752\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ticlopidine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (60): $111.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227754\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anagregal (IT);</li>\n      <li>Antigreg (MY, SG);</li>\n      <li>Aplaket (MY, TH);</li>\n      <li>Ban Su (CN);</li>\n      <li>Cartrilet (ID);</li>\n      <li>Cenpidine (TH);</li>\n      <li>Clid (KR);</li>\n      <li>Declot (TW);</li>\n      <li>Desitic (DE);</li>\n      <li>Ebrilon (MT);</li>\n      <li>Gotik (PY);</li>\n      <li>Ipaton (HU, RO, UA);</li>\n      <li>Licodin (TW);</li>\n      <li>Nichistate (TW);</li>\n      <li>Panaldine (JP);</li>\n      <li>Piclodin (ID);</li>\n      <li>Plaquetil (PY);</li>\n      <li>Prevoc (AE, BH, JO, QA, SA);</li>\n      <li>Strokan FC (MY);</li>\n      <li>Tagren (EE, HR);</li>\n      <li>Ticard (TH);</li>\n      <li>Ticlid (AE, AR, BB, BE, BH, BM, BO, BR, BS, BZ, CL, CO, CR, CY, CZ, DO, EC, EG, FR, GB, GR, GT, GY, HN, HU, IQ, IR, IS, JM, JO, KW, LB, LU, LY, MX, MY, NI, NL, NO, OM, PA, PE, PK, PR, PY, QA, SA, SE, SR, SV, SY, TH, TR, TT, UY, VE, YE);</li>\n      <li>Ticlidil (IL);</li>\n      <li>Ticlo (RU);</li>\n      <li>Ticlod (TW);</li>\n      <li>Ticlodin (RO);</li>\n      <li>Ticlodix (PT);</li>\n      <li>Ticlodone (GR, IT, KR);</li>\n      <li>Ticlop (JO);</li>\n      <li>Ticlopid (BD, BG);</li>\n      <li>Ticlopine (TH);</li>\n      <li>Ticolid (TH);</li>\n      <li>Ticopar (AE, KW, SA);</li>\n      <li>Ticuring (ID);</li>\n      <li>Tikleen (IN, VN);</li>\n      <li>Tiklid (AT, ES, IT);</li>\n      <li>Tiklyd (DE);</li>\n      <li>Tikpid (PH);</li>\n      <li>Tilodene (AU);</li>\n      <li>Tiodin (SG);</li>\n      <li>Tipidin (HK, MY, SG);</li>\n      <li>Tipidine (TH);</li>\n      <li>Tyklid (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adcirca (tadalafil) [prescribing informationt]. Indianapolis, IN: Eli Lilly and Company; April 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hass WK, Easton JD, Adams HP Jr, et al, &ldquo;A Randomized Trial Comparing Ticlopidine Hydrochloride With Aspirin for the Prevention of Stroke in High-Risk Patients,&rdquo; <i>N Engl J Med</i>, 1989, 321(8):501-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/2761587/pubmed\" target=\"_blank\" id=\"2761587\">2761587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindsay MP, Gubitz G, Bayley M, Phillips S; Canadian Stroke Best Practices and Standards Working Group. Canadian best practice recommendations for stroke care. <i>Stroke Prevention</i>. 4th ed. 2;2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticlopidine-united-states-not-available-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ticlopidine hydrochloride tablets [prescribing information]. Pulaski, TN: AvKARE Inc; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ticlopidine hydrochloride tablets [product monograph]. Toronto, Ontario, Canada: AA Pharma Inc; November 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9996 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709984\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F227763\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F227804\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F227767\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F227768\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6759555\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F6759556\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F227744\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F27727039\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F227747\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F227746\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9961827\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227736\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227750\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227733\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F227797\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227738\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F227759\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227740\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13459612\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17917341\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F227742\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227732\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F227749\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F227752\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F227754\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9996|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ticlopidine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Ticlopidine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}